ALRN-6924 vs Didemnin B
Head-to-head comparison of ALRN-6924 (ALRN-6924 dual MDM2/MDMX stapled p53 mimetic peptide) and Didemnin B (Didemnin B) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | ALRN-6924 | Didemnin B |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | ALRN-6924 dual MDM2/MDMX stapled p53 mimetic peptide | Didemnin B |
| Molecular Weight | N/A | 1112.4 Da |
| Half-Life | Hours to days depending on formulation | N/A |
| Amino Acids | N/A | N/A |
| Typical Dose | Varies by clinical protocol | 0.05-2 mg/m2 IV in early trials |
| Route | Intravenous/Subcutaneous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 40 | 120 |
| Research Status | Clinical | Clinical |
ALRN-6924 Benefits
- ✓p53 reactivation
- ✓dual MDM2/MDMX inhibition
- ✓protease resistance
- ✓tumor cell apoptosis
Didemnin B Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓immunomodulatory
ALRN-6924 Dosing
Clinical trial protocol dosing|Intermittent administration|Research-only escalation
Didemnin B Dosing
historic IV phase I/II oncology regimens|dose escalation in early trials|no approved dosing regimen
ALRN-6924 Side Effects
- ⚠nausea
- ⚠fatigue
- ⚠myelosuppression
Didemnin B Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠myelosuppression
Research Overview
ALRN-6924
ALRN-6924 is one of the best-known stapled peptide therapeutics and has advanced into human oncology studies. Literature shows that hydrocarbon stapling can improve target affinity, serum stability, and cellular activity for this p53-mimetic scaffold.
Didemnin B
Didemnin B showed strong cytotoxic and antiviral activity in early literature and became an important scaffold for later marine drug development. Its clinical progress was limited by toxicity, but it remains highly cited as a foundational marine depsipeptide.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.